Symptom-centric view

Breast cancer

Substances reporting Breast cancer disproportionately — ranked by ROR.

Pain Drug ineffective Off label use Fatigue Dyspnoea Acute kidney injury

showing 32 of 32

Substance ↓	ROR [95% CI]	Reports	Category	Label
vinorelbine —	4.8 [4.1–5.7]	145	algemeen	new
tamoxifen citrate —	8.7 [7.6–10.0]	217	algemeen	new
sodium iodide i 131 —	3.4 [2.1–5.5]	17	algemeen	new
sodium iodide i 123 —	4.0 [2.5–6.5]	17	algemeen	new
ribociclib —	6.2 [5.8–6.7]	837	algemeen	new
ranitidine hydrochloride —	40.0 [39.0–41.0]	7,734	algemeen	new
ranitidine —	46.6 [45.9–47.3]	29,413	algemeen	new
raloxifene hydrochloride —	4.6 [4.1–5.2]	300	algemeen	new
raloxifene —	4.2 [3.8–4.7]	302	algemeen	new
progesterone —	4.6 [4.2–5.1]	464	algemeen	new
pamidronate disodium —	4.0 [3.1–5.1]	60	algemeen	new
norethindrone acetate —	6.3 [5.7–7.0]	363	algemeen	new
norethindrone —	4.8 [4.3–5.3]	380	algemeen	new
medroxyprogesterone acetate —	66.9 [65.4–68.4]	10,966	algemeen	new
letrozole tablets —	6.4 [6.1–6.8]	1,310	algemeen	new
letrozole —	7.0 [6.6–7.3]	1,834	algemeen	new
lapatinib —	4.4 [3.9–4.9]	300	algemeen	new
goserelin —	3.9 [3.5–4.5]	231	algemeen	new
fulvestrant —	6.6 [6.1–7.0]	928	algemeen	new
folliculinum, oophorinum, —	6.7 [5.7–7.9]	148	algemeen	new
folliculinum, oophorinum (suis) —	6.7 [5.7–7.9]	148	algemeen	new
fingolimod hydrochloride —	3.6 [2.9–4.5]	77	algemeen	new
exemestane —	8.5 [7.9–9.1]	777	algemeen	new
estrogens, conjugated —	47.8 [46.8–48.9]	9,642	algemeen	new
estrogen —	4.1 [3.2–5.4]	54	algemeen	new
estradiol/norethindrone acetate —	38.3 [33.8–43.5]	282	algemeen	new
eribulin mesylate —	2.5 [1.9–3.4]	42	algemeen	new
conjugated estrogens and medroxyprogesterone acetate —	121.5 [118.2–125.0]	7,889	algemeen	new
conjugated estrogens —	53.5 [52.4–54.6]	12,143	algemeen	new
anastrozole tablets —	7.1 [6.6–7.7]	644	algemeen	new
anastrozole —	6.6 [6.2–7.0]	1,038	algemeen	new
alpelisib —	3.2 [2.7–3.8]	122	algemeen	new

ROR = reporting odds ratio vs. the full FAERS corpus. A signal is not a cause. Source: openFDA (FAERS).